Description
Terguride (37686-84-3) is a semi-synthetic ergoline derivative which acts as a partial dopamine D2 agonist and 5HT2B/2C receptor antagonist. Displays antiparkinsonian effects in MPTP-treated cynomolgus monkeys.1Partial agonist at recruitment of β-arrestin2 to the D2 receptor.2 Terguride ameliorates monocrotaline-induced pulmonary hypertension in rats.3
in vivo
TDHL abolished 5-HT-induced pulmonary vasoconstriction. Chronic terguride treatment prevented dose-dependently the development and progression of MCT-induced PAH in rats[1]. In reserpinized rats, terguride at 0.03 mg/kg, p.o. significantly reduces the serum prolactin (PRL) level. In rats bearing estrogen-induced pituitary prolactinoma, chronic terguride induces shrinkage of the prolactinoma as well as reduction of the high serum PRL level. In lactating rats, terguride (1.0 mg/kg, s.c.) reduces milk production in the mammary gland[2].
References
[1] TETSUO AKAI MS, PHD. Effects of terguride, a partial D2 agonist, on MPTP-lesioned parkinsonian cynomolgus monkeys[J]. Annals of Neurology, 1993, 33 5: 507-511. DOI:
10.1002/ana.410330515[2] IB V. KLEWE . Recruitment of β-arrestin2 to the dopamine D2 receptor: Insights into anti-psychotic and anti-parkinsonian drug receptor signaling[J]. Neuropharmacology, 2008, 54 8: Pages 1215-1222. DOI:
10.1016/j.neuropharm.2008.03.015[3] R DUMITRASCU. Terguride ameliorates monocrotaline-induced pulmonary hypertension in rats.[J]. European Respiratory Journal, 2011, 37 5: 1104-1118. DOI:
10.1183/09031936.00126010
![S(+)-N,N-diethyl-n'([8alpha]-6-methylergolin-8-yl)urea Structure](https://www.chemicalbook.com/CAS/GIF/37686-84-3.gif)
